UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
Teva and Sanofi presented new Phase 2b long-term extension data at UEG Week 2026 showing duvakitug maintained durable efficacy through 44 weeks of maintenance in ulcerative colitis and Crohn's disease. In UC, 58% of patients on the 900 mg dose achieved clinical remission; in CD, 900 mg delivered 55% endoscopic response and 84% clinical remission, with a consistent dose-response trend and no new safety signals.
Key figures
- Drug Name
- duvakitug
- Phase Of Trial
- Phase 2b long-term extension (Phase 3 ongoing)
- Patients lte
- 130
- Uc week44 clinical response 900mg
- 87%
- Cd week44 clinical remission 900mg
- 84%
- Uc week44 clinical remission 450mg
- 47%
- Uc week44 clinical remission 900mg
- 58%
- Cd week44 endoscopic response 900mg
- 55%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.